Eli Lilly and Company $LLY Shares Sold by Picton Mahoney Asset Management

Picton Mahoney Asset Management lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 33.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,253 shares of the company’s stock after selling 14,470 shares during the period. Picton Mahoney Asset Management’s holdings in Eli Lilly and Company were worth $22,320,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Laurel Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after buying an additional 11,537,661 shares during the period. Norges Bank purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at approximately $8,827,714,000. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after acquiring an additional 1,183,038 shares during the period. Victory Capital Management Inc. lifted its position in Eli Lilly and Company by 47.6% during the 3rd quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company’s stock worth $1,761,772,000 after acquiring an additional 744,868 shares during the period. Finally, Franklin Resources Inc. grew its stake in shares of Eli Lilly and Company by 13.4% in the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock valued at $3,715,913,000 after purchasing an additional 564,736 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly says it is preparing to launch its oral obesity drug orforglipron in the U.S. as soon as Q2 pending FDA approval — a major revenue catalyst if approved and on schedule. Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
• Positive Sentiment: Lilly won CHMP backing to expand Olumiant (baricitinib) use in adolescents with severe alopecia areata, which could broaden EU label and incremental sales. LLY Wins CHMP Nod for Olumiant’s Expanded Use in Alopecia Areata
• Positive Sentiment: Lilly advanced remternetug Alzheimer’s testing in China, extending its CNS pipeline geography and potential long‑term growth optionality outside the U.S. Lilly Advances Remternetug Testing in China
• Positive Sentiment: Lilly advanced a Phase 1 oral diabetes candidate in China, reinforcing its diabetes/GLP pipeline breadth beyond injectable and obesity programs. Eli Lilly Advances New Oral Diabetes Drug In China
• Neutral Sentiment: Analyst coverage remains constructive overall (average “Moderate Buy”) and industry outlooks highlight Lilly as a core large‑cap pharma to watch, supporting longer‑term investor interest. Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Investor attention pieces and conference transcripts (TD Cowen) are circulating — helpful for transparency but not immediate stock drivers. TD Cowen Presentation Transcript
• Negative Sentiment: Competitive pressure: Novo Nordisk’s $506M expansion in Ireland signals stronger manufacturing scale for oral GLP medicines, a direct competitor to Lilly’s obesity/GLP lineup and a potential market‑share headwind. Why Novo Nordisk’s Ireland expansion is key
• Negative Sentiment: Some editorial/analyst pieces argue investors should consider alternatives or note that Lilly’s valuation and recent momentum have cooled after a multi‑year run, increasing sensitivity to any negative headlines. Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,007.37 on Wednesday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The firm has a market capitalization of $950.31 billion, a P/E ratio of 43.89, a PEG ratio of 1.18 and a beta of 0.40. The company’s fifty day moving average is $1,050.71 and its two-hundred day moving average is $936.44.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter last year, the business earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is presently 30.15%.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Freedom Capital upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Scotiabank reissued an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Cantor Fitzgerald upped their price objective on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Finally, Wolfe Research boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,229.59.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.